Phase II clinic trial for the reduction of time of haematopoietic stem cell engraftment with sitagliptin in patients with multiple myeloma receiving autologous transplantation.

Trial Profile

Phase II clinic trial for the reduction of time of haematopoietic stem cell engraftment with sitagliptin in patients with multiple myeloma receiving autologous transplantation.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2012

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Oct 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 07 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top